Filtered By:
Cancer: Prostate Cancer
Drug: Fortamet
This page shows you your search results in order of date.
Order by Relevance | Date
Total 75 results found since Jan 2013.
Oxidative brain and cerebellum injury in diabetes and prostate cancer model: Protective effect of metformin
J Biochem Mol Toxicol. 2023 Jun 24:e23440. doi: 10.1002/jbt.23440. Online ahead of print.ABSTRACTThe body can host the spread of prostate cancer cells. Metastases from prostate cancer are more frequently seen in the brain, liver, lungs, and lymph nodes. A well-known antidiabetic drug, metformin, is also known to have antitumor effects. Our study focuses on the evaluation of potential metformin protective effects on brain and cerebellum damage in streptozotocin (STZ)-induced diabetic and Dunning prostate cancer models. In this investigation, six groups of male Copenhagen rats were created: control, diabetic (D), cancer (C),...
Source: Cancer Control - June 24, 2023 Category: Cancer & Oncology Authors: Eda Dagsuyu P ınar Koroglu Ilknur B Gul Omur K Bulan Refiye Yanardag Source Type: research
Drug repurposing: Metformin's effect against liver tissue damage in diabetes and prostate cancer model
CONCLUSION: These highlights that the antidiabetic drug metformin can be repositioned for attenuating liver tissue damage associated with prostate cancer and diabetes.PMID:37255805 | PMC:PMC10225428 | DOI:10.1007/s40200-022-01109-w
Source: Cancer Control - May 31, 2023 Category: Cancer & Oncology Authors: P ınar Koroglu Aydın Ismet Burcu Turky ılmaz Ilknur Bugan Gul Omur Karabulut Bulan Refiye Yanardag Source Type: research
Strategies to Re-Sensitize Castration-Resistant Prostate Cancer to Antiandrogen Therapy
Biomedicines. 2023 Apr 6;11(4):1105. doi: 10.3390/biomedicines11041105.ABSTRACTSince prostate cancer (PCa) was described as androgen-dependent, the androgen receptor (AR) has become the mainstay of its systemic treatment: androgen deprivation therapy (ADT). Although, through recent years, more potent drugs have been incorporated, this chronic AR signaling inhibition inevitably led the tumor to an incurable phase of castration resistance. However, in the castration-resistant status, PCa cells remain highly dependent on the AR signaling axis, and proof of it is that many men with castration-resistant prostate cancer (CRPC) s...
Source: Cancer Control - May 16, 2023 Category: Cancer & Oncology Authors: Bel én Congregado Ruiz In és Rivero Belenchón Guillermo Lend ínez Cano Rafael Antonio Medina L ópez Source Type: research
Network toxicology prediction and molecular docking-based strategy to explore the potential toxicity mechanism of Metformin chlorination byproducts in drinking water
CONCLUSION: This study preliminarily revealed the potential toxicity and possible toxicity mechanism of metformin disinfection by-products and provided a new idea for follow-up research.PMID:37170985 | DOI:10.2174/1386207326666230426105412
Source: Combinatorial Chemistry and High Throughput Screening - May 12, 2023 Category: Chemistry Authors: Gui-Hong Zhang Hongwei Liu Mei-Hua Liu Yang-Cheng Liu Jia-Qi Wang Yang Wang Xin Wang Zheng Xiang Wei Liu Source Type: research
New insight in urological cancer therapy: From epithelial-mesenchymal transition (EMT) to application of nano-biomaterials
Environ Res. 2023 Mar 9:115672. doi: 10.1016/j.envres.2023.115672. Online ahead of print.ABSTRACTA high number of cancer-related deaths (up to 90) are due to metastasis and simple definition of metastasis is new colony formation of tumor cells in a secondary site. In tumor cells, epithelial-mesenchymal transition (EMT) stimulates metastasis and invasion, and it is a common characteristic of malignant tumors. Prostate cancer, bladder cancer and renal cancer are three main types of urological tumors that their malignant and aggressive behaviors are due to abnormal proliferation and metastasis. EMT has been well-documented as...
Source: Environmental Research - March 11, 2023 Category: Environmental Health Authors: Peng He Qiang Dai Xiaojun Wu Source Type: research
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer
CONCLUSIONS: Among patients with mHSPC, use of metformin was not significantly associated with improved OS in the multivariate analysis.PMID:36744171 | PMC:PMC9896090 | DOI:10.1177/11795549231152073
Source: Clinical Prostate Cancer - February 6, 2023 Category: Cancer & Oncology Authors: Chung-Shien Lee So Yi Lam Angel Liu Cristina Sison Xin-Hua Zhu Source Type: research
Targeting lipid metabolism in metastatic prostate cancer
Ther Adv Med Oncol. 2023 Jan 30;15:17588359231152839. doi: 10.1177/17588359231152839. eCollection 2023.ABSTRACTDespite key advances in the treatment of prostate cancer (PCa), a proportion of men have de novo resistance, and all will develop resistance to current therapeutics over time. Aberrant lipid metabolism has long been associated with prostate carcinogenesis and progression, but more recently there has been an explosion of preclinical and clinical data which is informing new clinical trials. This review explores the epidemiological links between obesity and metabolic syndrome and PCa, the evidence for altered circula...
Source: Adv Data - February 6, 2023 Category: Epidemiology Authors: Tahlia Scheinberg Blossom Mak Lisa Butler Luke Selth Lisa G Horvath Source Type: research
A Retrospective Study of the Effect of Metformin on Patients with Metastatic Prostate Cancer
CONCLUSIONS: Among patients with mHSPC, use of metformin was not significantly associated with improved OS in the multivariate analysis.PMID:36744171 | PMC:PMC9896090 | DOI:10.1177/11795549231152073
Source: Clinical Prostate Cancer - February 6, 2023 Category: Cancer & Oncology Authors: Chung-Shien Lee So Yi Lam Angel Liu Cristina Sison Xin-Hua Zhu Source Type: research
Metformin use and hospital attendance-related resources utilization among diabetic patients with prostate cancer on androgen deprivation therapy: A population-based cohort study
CONCLUSIONS: Metformin use was associated with decreased hospital attendances, days of hospitalization, and associated costs, which could help reduce healthcare resource utilization following ADT in the treatment of PCa.PMID:36734312 | DOI:10.1002/cam4.5651
Source: Cancer Control - February 3, 2023 Category: Cancer & Oncology Authors: Yan Hiu Athena Lee Jeremy Man Ho Hui Cheuk To Chung Kang Liu Edward Christopher Dee Kenrick Ng Gary Tse Jeffrey Shi Kai Chan Chi Fai Ng Source Type: research
Metformin: new applications for an old drug
J Basic Clin Physiol Pharmacol. 2022 Dec 7. doi: 10.1515/jbcpp-2022-0252. Online ahead of print.NO ABSTRACTPMID:36474458 | DOI:10.1515/jbcpp-2022-0252
Source: Clinical Prostate Cancer - December 7, 2022 Category: Cancer & Oncology Authors: Amirreza Naseri Sarvin Sanaie Sina Hamzehzadeh Sepideh Seyedi-Sahebari Mohammad-Salar Hosseini Elnaz Gholipour-Khalili Ehsan Rezazadeh-Gavgani Reza Majidazar Parya Seraji Sara Daneshvar Erfan Rezazadeh-Gavgani Source Type: research
